Modality
Small Molecule
MOA
FXIai
Target
SOS1
Pathway
Wnt
Ewing SarcomaPNH
Development Pipeline
Preclinical
Nov 2021
→ Feb 2027
PreclinicalCurrent
NCT04695176
1,750 pts·Ewing Sarcoma
2021-11→2027-02·Active
1,750 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-1110mo awayInterim· Ewing Sarcoma
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
Preclinical
Active
Catalysts
Interim
2027-02-11 · 10mo away
Ewing Sarcoma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04695176 | Preclinical | Ewing Sarcoma | Active | 1750 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |